<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7472297\results\search\disease\results.xml">
  <result pre="7472297 doi: 10.3390/v12080852viruses-12-00852 : Review Contribution of Human Retroviruses to" exact="Disease" post="Developmentâ€&quot;A Focus on the HIVâ€&quot; and HERVâ€&quot;Cancer Relationships and"/>
  <result pre="of the potent causative agents in various disease, including specific" exact="cancer" post="types. For instance, Human T Lymphotropic virus (HTLV) is"/>
  <result pre="well-studied class of oncoviruses causing T cell leukemia, while human" exact="immunodeficiency" post="virus (HIV) leads to acquired immunodeficiency syndrome (AIDS), which"/>
  <result pre="T cell leukemia, while human immunodeficiency virus (HIV) leads to" exact="acquired immunodeficiency syndrome" post="(AIDS), which is linked to a series of defining"/>
  <result pre="cell leukemia, while human immunodeficiency virus (HIV) leads to acquired" exact="immunodeficiency" post="syndrome (AIDS), which is linked to a series of"/>
  <result pre="leukemia, while human immunodeficiency virus (HIV) leads to acquired immunodeficiency" exact="syndrome" post="(AIDS), which is linked to a series of defining"/>
  <result pre="which is linked to a series of defining cancers including" exact="Kaposi sarcoma," post="certain types of non-Hodgkin lymphoma, and cervical cancer. Of"/>
  <result pre="series of defining cancers including Kaposi sarcoma, certain types of" exact="non-Hodgkin lymphoma," post="and cervical cancer. Of note, in addition to these"/>
  <result pre="cancers including Kaposi sarcoma, certain types of non-Hodgkin lymphoma, and" exact="cervical cancer." post="Of note, in addition to these â€œmodernâ€� exogenous retroviruses,"/>
  <result pre="(HERVs). HERVs are the genetic remnants of ancient retroviral germline" exact="infection" post="of human ancestors and are typically silenced in normal"/>
  <result pre="also been targeted as a potential internal strategy to sensitize" exact="tumor" post="cells for promising immunotherapies. In this review, we discuss"/>
  <result pre="review, we discuss the dynamic role of human retroviruses in" exact="cancer" post="development, focusing on HIV and HERVs contribution. We also"/>
  <result pre="be employed as prospective anti-cancer modalities. human endogenous retroviruses human" exact="immunodeficiency" post="virus carcinogenesis cancer treatment antiviral strategies immunotherapy 1. Introduction"/>
  <result pre="prospective anti-cancer modalities. human endogenous retroviruses human immunodeficiency virus carcinogenesis" exact="cancer" post="treatment antiviral strategies immunotherapy 1. Introduction Retroviruses are a"/>
  <result pre="of animal retroviruses led to their original definition as â€œRNA" exact="tumor" post="virusesâ€� [1]. Currently, there are two exogenous retroviruses affecting"/>
  <result pre="Currently, there are two exogenous retroviruses affecting human health: human" exact="immunodeficiency" post="virus (HIV) and human T lymphotropic virus (HTLV). While"/>
  <result pre="(HTLV). While HTLV is a â€œclassicalâ€� oncovirus, causing T cell" exact="leukemia" post="as its main etiological manifestation, HIV infection is responsible"/>
  <result pre="oncovirus, causing T cell leukemia as its main etiological manifestation," exact="HIV infection" post="is responsible for acquired immunodeficiency syndrome (AIDS), which is"/>
  <result pre="causing T cell leukemia as its main etiological manifestation, HIV" exact="infection" post="is responsible for acquired immunodeficiency syndrome (AIDS), which is"/>
  <result pre="as its main etiological manifestation, HIV infection is responsible for" exact="acquired immunodeficiency syndrome" post="(AIDS), which is accompanied by a number of comorbidities,"/>
  <result pre="its main etiological manifestation, HIV infection is responsible for acquired" exact="immunodeficiency" post="syndrome (AIDS), which is accompanied by a number of"/>
  <result pre="main etiological manifestation, HIV infection is responsible for acquired immunodeficiency" exact="syndrome" post="(AIDS), which is accompanied by a number of comorbidities,"/>
  <result pre="contains endogenous retroviruses (ERVs), which are ancient traces of past" exact="infections" post="found as viral footprints in the genome of the"/>
  <result pre="(ERVs), which are ancient traces of past infections found as" exact="viral" post="footprints in the genome of the various species. The"/>
  <result pre="have been recently classified into 39 main groups [3]. These" exact="viral" post="footprints are virus-associated sequences that closely resemble present-day retroviral"/>
  <result pre="and deletions, which have generally affected their capacity to produce" exact="infectious" post="virions [5]. Viruses of the Retroviridae family typically contain"/>
  <result pre="steps of HIV into the targeted host cells, whereas the" exact="viral" post="enzymatic activities (reverse transcriptase (RT), RNase H, integrase (IN),"/>
  <result pre="protease (PR)) encoded by the pro-pol gene are crucial to" exact="viral" post="replication [6]. Retroviruses are characterized by their ability to"/>
  <result pre="remnants of ancient exogenous retroviruses resulted from their germ line" exact="infection" post="and integration in vertebrate ancestors approximately over 100 million"/>
  <result pre="HERV and the development of novel anti-cancer strategies for HERV-associated" exact="cancer" post="scenarios. Although HTLV is also an onco-retrovirus, evidence for"/>
  <result pre="is also an onco-retrovirus, evidence for treating HTLV-associated T cell" exact="leukemia" post="with antiretroviral therapy remains limited. Currently, only the combination"/>
  <result pre="at the beginning of the 1980s, the manifestations associated with" exact="immunodeficiency" post="included Kaposiâ€™s sarcoma, aggressive B cell lymphomas, and invasive"/>
  <result pre="immunodeficiency included Kaposiâ€™s sarcoma, aggressive B cell lymphomas, and invasive" exact="cervical cancer." post="These malignancies were commonly found in AIDS patients and"/>
  <result pre="number of other malignancies are known to be associated to" exact="HIV infection," post="even if non-AIDS-defining, showing an increased incidence among HIV"/>
  <result pre="an increased incidence among HIV patients. These HIV-associated cancers include" exact="lung cancer," post="hepatocellular carcinoma, Hodgkinâ€™s lymphoma, oropharyngeal cancers, and anal and"/>
  <result pre="incidence among HIV patients. These HIV-associated cancers include lung cancer," exact="hepatocellular carcinoma," post="Hodgkinâ€™s lymphoma, oropharyngeal cancers, and anal and genital cancers"/>
  <result pre="cancers, and anal and genital cancers [2]. The overall augmented" exact="cancer" post="risk in HIV-infected individuals is driven by multiple factors."/>
  <result pre="on the host immune system, create a dysregulated environment triggering" exact="cancer" post="development by both immunosuppression, which can aid in the"/>
  <result pre="which can aid in the immune evasion of oncoviruses and" exact="cancer" post="cells, and chronic inflammation, which promotes cellular proliferation hence"/>
  <result pre="in the immune evasion of oncoviruses and cancer cells, and" exact="chronic" post="inflammation, which promotes cellular proliferation hence tumorigenesis [12,13]. Behavioral"/>
  <result pre="sexual contacts or drug users, also contribute to the increased" exact="cancer" post="risk [14]. Notably, the development of effective antiretroviral drugs"/>
  <result pre="currently in the age range that is associated with augmented" exact="cancer" post="risk [15]. As a consequence of an aging HIV-infected"/>
  <result pre="occurrence of malignancies [16]. 3. AIDS-Defining HIV-Associated Cancers The first" exact="cancer" post="historically connected to AIDSâ€™ presence was Kaposiâ€™s sarcoma, characterized"/>
  <result pre="mucosa, gastrointestinal tract, lymph nodes, lungs, and bones [2]. Kaposiâ€™s" exact="sarcoma" post="is caused by human herpesvirus 8, also known as"/>
  <result pre="known as Kaposiâ€™s sarcoma-associated herpesvirus (KSHV). KSHV does not require" exact="HIV infection" post="to develop Kaposiâ€™s sarcoma, but the immune dysregulation induced"/>
  <result pre="as Kaposiâ€™s sarcoma-associated herpesvirus (KSHV). KSHV does not require HIV" exact="infection" post="to develop Kaposiâ€™s sarcoma, but the immune dysregulation induced"/>
  <result pre="in HIV patients, sustaining carcinogenesis. Accordingly, the risk of Kaposiâ€™s" exact="sarcoma" post="in HIV patients is inversely related to their CD4+"/>
  <result pre="relatively high CD4+ T cell count still had persistent Kaposiâ€™s" exact="sarcoma" post="[17]. The second group of AIDS-defining cancer is represented"/>
  <result pre="had persistent Kaposiâ€™s sarcoma [17]. The second group of AIDS-defining" exact="cancer" post="is represented by aggressive B cell non-Hodgkinâ€™s lymphomas [2]."/>
  <result pre="represented by aggressive B cell non-Hodgkinâ€™s lymphomas [2]. Of which," exact="primary" post="central nervous system lymphoma and plasmablastic lymphoma often consist"/>
  <result pre="by aggressive B cell non-Hodgkinâ€™s lymphomas [2]. Of which, primary" exact="central nervous system" post="lymphoma and plasmablastic lymphoma often consist of cells infected"/>
  <result pre="cell non-Hodgkinâ€™s lymphomas [2]. Of which, primary central nervous system" exact="lymphoma" post="and plasmablastic lymphoma often consist of cells infected by"/>
  <result pre="lymphomas [2]. Of which, primary central nervous system lymphoma and" exact="plasmablastic lymphoma" post="often consist of cells infected by Epstein Barr virus"/>
  <result pre="[2]. Of which, primary central nervous system lymphoma and plasmablastic" exact="lymphoma" post="often consist of cells infected by Epstein Barr virus"/>
  <result pre="of cells infected by Epstein Barr virus (EBV), while Burkittâ€™s" exact="lymphoma" post="and diffuse large B cell lymphoma are mainly negative"/>
  <result pre="infected by Epstein Barr virus (EBV), while Burkittâ€™s lymphoma and" exact="diffuse" post="large B cell lymphoma are mainly negative for EBV"/>
  <result pre="virus (EBV), while Burkittâ€™s lymphoma and diffuse large B cell" exact="lymphoma" post="are mainly negative for EBV [2]. Although the overall"/>
  <result pre="population [18,19]. The third and last AIDS-defining malignancy is invasive" exact="cervical cancer," post="whose risk is increased in HIV-infected women, being associated"/>
  <result pre="count [20]. Overall, almost all cervical cancers arise from human" exact="papilloma" post="virus (HPV) oncogenesis, and the concomitant presence of HIV"/>
  <result pre="host immune response and thus preventing the clearance of HPV" exact="infection" post="[13]. 4. Other HIV-Associated Cancers Besides the above AIDS-defining"/>
  <result pre="[13]. 4. Other HIV-Associated Cancers Besides the above AIDS-defining cancers," exact="HIV infection" post="is associated with increased incidence of a number of"/>
  <result pre="4. Other HIV-Associated Cancers Besides the above AIDS-defining cancers, HIV" exact="infection" post="is associated with increased incidence of a number of"/>
  <result pre="number of other malignancies. The most frequent HIV-associated cancers include" exact="lung cancer," post="hepatocellular carcinoma, Hodgkinâ€™s lymphoma, oropharyngeal cancers, as well as"/>
  <result pre="other malignancies. The most frequent HIV-associated cancers include lung cancer," exact="hepatocellular carcinoma," post="Hodgkinâ€™s lymphoma, oropharyngeal cancers, as well as genital and"/>
  <result pre="affecting the oropharynx, genitals and anus are linked to HPV" exact="infection" post="as well [2,21]. In fact, as mentioned for cervical"/>
  <result pre="HPV infection as well [2,21]. In fact, as mentioned for" exact="cervical cancer," post="HIV-infected individuals present immunosuppression that is linked to a"/>
  <result pre="that is linked to a higher risk to establish a" exact="chronic" post="HPV infection and develop pre-malignant high-grade intraepithelial lesions [13,22]."/>
  <result pre="linked to a higher risk to establish a chronic HPV" exact="infection" post="and develop pre-malignant high-grade intraepithelial lesions [13,22]. As for"/>
  <result pre="infection and develop pre-malignant high-grade intraepithelial lesions [13,22]. As for" exact="hepatocellular carcinoma," post="its etiological agent hepatitis virus B and C (HBV"/>
  <result pre="intraepithelial lesions [13,22]. As for hepatocellular carcinoma, its etiological agent" exact="hepatitis" post="virus B and C (HBV and HCV, respectively) are"/>
  <result pre="thus often co-infect with HIV. This increases the incidence of" exact="hepatocellular carcinoma" post="in HIV patients, with similar cancer progression in non-HIV-infected"/>
  <result pre="often co-infect with HIV. This increases the incidence of hepatocellular" exact="carcinoma" post="in HIV patients, with similar cancer progression in non-HIV-infected"/>
  <result pre="the incidence of hepatocellular carcinoma in HIV patients, with similar" exact="cancer" post="progression in non-HIV-infected individuals with chronic viral hepatitis [13]."/>
  <result pre="HIV patients, with similar cancer progression in non-HIV-infected individuals with" exact="chronic" post="viral hepatitis [13]. Concerning non-AIDS defining lymphomas associated to"/>
  <result pre="patients, with similar cancer progression in non-HIV-infected individuals with chronic" exact="viral hepatitis" post="[13]. Concerning non-AIDS defining lymphomas associated to HIV infection,"/>
  <result pre="with similar cancer progression in non-HIV-infected individuals with chronic viral" exact="hepatitis" post="[13]. Concerning non-AIDS defining lymphomas associated to HIV infection,"/>
  <result pre="chronic viral hepatitis [13]. Concerning non-AIDS defining lymphomas associated to" exact="HIV infection," post="they are also often caused by the concomitant infection"/>
  <result pre="HIV infection, they are also often caused by the concomitant" exact="infection" post="with transforming viruses, such as EBV and KSHV. Pharmacological"/>
  <result pre="HIV has not been able to reduce the incidence of" exact="Hodgkin lymphoma" post="in infected individuals, but recent findings suggest that prolonged"/>
  <result pre="has not been able to reduce the incidence of Hodgkin" exact="lymphoma" post="in infected individuals, but recent findings suggest that prolonged"/>
  <result pre="lymphomas, individuals infected with HIV tend to show extranodal and" exact="central nervous system" post="involvement [24] and elevated cancer-specific mortality [25] as compared"/>
  <result pre="elevated cancer-specific mortality [25] as compared to the general population." exact="Lung cancer" post="is another malignancy reported to have higher incidence in"/>
  <result pre="cancer-specific mortality [25] as compared to the general population. Lung" exact="cancer" post="is another malignancy reported to have higher incidence in"/>
  <result pre="smokers [27], but also on HIV-related factors such as elevated" exact="susceptibility to" post="pneumonia and chronic obstructive pulmonary disease, which contribute to"/>
  <result pre="but also on HIV-related factors such as elevated susceptibility to" exact="pneumonia" post="and chronic obstructive pulmonary disease, which contribute to a"/>
  <result pre="on HIV-related factors such as elevated susceptibility to pneumonia and" exact="chronic" post="obstructive pulmonary disease, which contribute to a higher risk"/>
  <result pre="factors such as elevated susceptibility to pneumonia and chronic obstructive" exact="pulmonary" post="disease, which contribute to a higher risk of lung"/>
  <result pre="addition to the above HIV-associated tumors, the presence of the" exact="infection" post="augments the risk of incidental cancers as well, including"/>
  <result pre="squamous-cell skin cancers [2]. 5. Immunotherapeutic Strategies Targeting HIV for" exact="Cancer" post="Treatment Given the clear association between HIV infection and"/>
  <result pre="Targeting HIV for Cancer Treatment Given the clear association between" exact="HIV infection" post="and the increased incidence of human malignancies, a number"/>
  <result pre="HIV for Cancer Treatment Given the clear association between HIV" exact="infection" post="and the increased incidence of human malignancies, a number"/>
  <result pre="HIV-associated tumors depend on co-infection with known oncoviruses, a significant" exact="cancer" post="prevention clue is represented by the vaccinations available against"/>
  <result pre="and hepatocellular cancers, respectively. Similarly, screening procedures are crucial for" exact="cancer" post="prevention and early diagnosis, not only in HIV-infected patients"/>
  <result pre="general population. Another important action is the early diagnosis of" exact="HIV infection," post="allowing for the prompt initiation of effective ART before"/>
  <result pre="that early and uninterrupted ART can reduce the risk of" exact="cancer" post="associated with HIV infection, restoring CD4+ T cell count"/>
  <result pre="uninterrupted ART can reduce the risk of cancer associated with" exact="HIV infection," post="restoring CD4+ T cell count and limiting oncovirusesâ€™ immune"/>
  <result pre="and limiting oncovirusesâ€™ immune evasion [15]. Accordingly, the risk of" exact="cancer" post="was decreased by approximately two-thirds in HIV patients who"/>
  <result pre="[30]. Finally, the prevention of behavioral factors that increase HIV-associated" exact="cancer" post="incidence, such as smoking for lung cancer or unprotected"/>
  <result pre="factors that increase HIV-associated cancer incidence, such as smoking for" exact="lung cancer" post="or unprotected sex for sexually transmitted oncoviruses, can play"/>
  <result pre="that increase HIV-associated cancer incidence, such as smoking for lung" exact="cancer" post="or unprotected sex for sexually transmitted oncoviruses, can play"/>
  <result pre="Physiological Implications of HERV Elements As mentioned above, ERVs are" exact="viral" post="footprints that are found in the host genomes. Over"/>
  <result pre="by a HERV-FRD provirus env, are thought to have been" exact="acquired" post="by the primates many millions ago (~25 million years"/>
  <result pre="the primate evolution, observing high degree of conservation and very" exact="limited" post="human polymorphisms [36,37]. In addition, HERVs play a role"/>
  <result pre="elicit both positive antiviral protection against exogenous viruses and negative" exact="autoimmune" post="and inflammatory disease-inducing effects (further discussed below). These observations"/>
  <result pre="in a number of human diseases, such as cancers [41]," exact="autoimmune diseases" post="[42], and neurological diseases [43], possibly suggesting their role"/>
  <result pre="or exogenous microorganisms [44]. Interestingly, recent studies suggest that several" exact="viral" post="infections, such as retroviruses (HIV, HTLV-1), herpesviruses (EBV, herpes"/>
  <result pre="several viral infections, such as retroviruses (HIV, HTLV-1), herpesviruses (EBV," exact="herpes" post="simplex virus type 1 (HSV-1), KSHV), HBV, and influenza"/>
  <result pre="such as retroviruses (HIV, HTLV-1), herpesviruses (EBV, herpes simplex virus" exact="type 1" post="(HSV-1), KSHV), HBV, and influenza virus, can transactivate HERV"/>
  <result pre="pathogenicity of certain viruses, including those that lead to long-term" exact="disease" post="development such as autoimmune diseases and cancers. In the"/>
  <result pre="including those that lead to long-term disease development such as" exact="autoimmune diseases" post="and cancers. In the case of cancer, a considerable"/>
  <result pre="Many studies attempted to illustrate the role of HERV in" exact="cancer" post="[46], as HERV elements and HERV-encoded proteins were found"/>
  <result pre="and HERV-encoded proteins were found in a variety of cancers" exact="including melanoma," post="breast cancer, colorectal cancer, hepatobiliary cancers, prostate cancer, ovarian"/>
  <result pre="proteins were found in a variety of cancers including melanoma," exact="breast cancer," post="colorectal cancer, hepatobiliary cancers, prostate cancer, ovarian cancer, and"/>
  <result pre="found in a variety of cancers including melanoma, breast cancer," exact="colorectal cancer," post="hepatobiliary cancers, prostate cancer, ovarian cancer, and germ cell"/>
  <result pre="of cancers including melanoma, breast cancer, colorectal cancer, hepatobiliary cancers," exact="prostate cancer," post="ovarian cancer, and germ cell tumors [44,47,48]. As such,"/>
  <result pre="including melanoma, breast cancer, colorectal cancer, hepatobiliary cancers, prostate cancer," exact="ovarian cancer," post="and germ cell tumors [44,47,48]. As such, HERV elements"/>
  <result pre="(ERVHâˆ’5, ERVH48âˆ’1, and ERVEâˆ’4 in the study) was found in" exact="glioma" post="and thyroid cancer [50]. In another study by Bergallo"/>
  <result pre="and ERVEâˆ’4 in the study) was found in glioma and" exact="thyroid cancer" post="[50]. In another study by Bergallo et al., while"/>
  <result pre="ERVEâˆ’4 in the study) was found in glioma and thyroid" exact="cancer" post="[50]. In another study by Bergallo et al., while"/>
  <result pre="Bergallo et al., while HERV-K pol was overexpressed in pediatric" exact="acute lymphoblastic leukemia" post="(ALL) patients, the expression level was not significantly increased"/>
  <result pre="et al., while HERV-K pol was overexpressed in pediatric acute" exact="lymphoblastic leukemia" post="(ALL) patients, the expression level was not significantly increased"/>
  <result pre="al., while HERV-K pol was overexpressed in pediatric acute lymphoblastic" exact="leukemia" post="(ALL) patients, the expression level was not significantly increased"/>
  <result pre="the expression level was not significantly increased in those with" exact="acute" post="myeloid leukemia (AML) [51]. In contrast, Januszkiewicz-Lewandowska et al."/>
  <result pre="expression level was not significantly increased in those with acute" exact="myeloid leukemia" post="(AML) [51]. In contrast, Januszkiewicz-Lewandowska et al. demonstrated that"/>
  <result pre="level was not significantly increased in those with acute myeloid" exact="leukemia" post="(AML) [51]. In contrast, Januszkiewicz-Lewandowska et al. demonstrated that"/>
  <result pre="suggest that HERV elements may not be overexpressed in all" exact="cancer" post="types, and that different groups and different parts of"/>
  <result pre="as the hypomethylation of DNA and chromatin remodeling in the" exact="cancer" post="cells, which could expose previously silent HERV LTRs [53]."/>
  <result pre="revealed that HERVs may contribute to host defense responses against" exact="cancer" post="[54], implicating their presence as participants rather than mere"/>
  <result pre="bystanders. As a result, the precise role of HERV in" exact="cancer" post="development remains to be fully clarified, but several observations"/>
  <result pre="the evolving paradigm of HERV-cancer association. 8. HERV Contribution to" exact="Cancer" post="at the Genome Level Potentially oncogenic properties of HERV"/>
  <result pre="that contributes to tumorigenesis [54]. Such effects were seen in" exact="prostate cancer" post="[55], melanoma, Hodgkinâ€™s lymphoma, diffuse large B cell lymphoma,"/>
  <result pre="contributes to tumorigenesis [54]. Such effects were seen in prostate" exact="cancer" post="[55], melanoma, Hodgkinâ€™s lymphoma, diffuse large B cell lymphoma,"/>
  <result pre="effects were seen in prostate cancer [55], melanoma, Hodgkinâ€™s lymphoma," exact="diffuse" post="large B cell lymphoma, etc. [53], where abnormal gene"/>
  <result pre="cells [56], while HERV-W has been detected in cancer-stem like" exact="colorectal cancer" post="cells [57]. It has also been shown in melanoma"/>
  <result pre="[56], while HERV-W has been detected in cancer-stem like colorectal" exact="cancer" post="cells [57]. It has also been shown in melanoma"/>
  <result pre="colorectal cancer cells [57]. It has also been shown in" exact="melanoma" post="cells that HERV-K(HML2) activation promotes phenotype-switching to obtain cancer"/>
  <result pre="in melanoma cells that HERV-K(HML2) activation promotes phenotype-switching to obtain" exact="cancer" post="stem-like features [58]. It would be interesting to explore"/>
  <result pre="explore whether HERV contributes to the stemness or pluripotency in" exact="cancer" post="stem cells in a similar way as in embryonic"/>
  <result pre="common regulatory factors they share [44]. 9. HERV Contribution to" exact="Cancer" post="at the Protein Level At the protein level, some"/>
  <result pre="they share [44]. 9. HERV Contribution to Cancer at the" exact="Protein" post="Level At the protein level, some Env proteins promote"/>
  <result pre="fusion, immunosuppression, and cell signaling pathways that are crucial for" exact="cancer" post="development [54]. In the case of breast cancer, HERV-K"/>
  <result pre="are crucial for cancer development [54]. In the case of" exact="breast cancer," post="HERV-K Env protein plays an important role in tumorigenesis"/>
  <result pre="HERV-K Env protein plays an important role in tumorigenesis and" exact="metastasis" post="through activating the Ras-ERK pathway [59]. Anti-HERV-K Env antibodies"/>
  <result pre="receptor (CAR) T cells exhibited significant tumor-specific cytotoxicity and prevented" exact="metastasis" post="in mouse xenograft models [60,61]. In the case of"/>
  <result pre="was found to be targeted by cytotoxic T cells in" exact="melanoma" post="patients [62]. HERV-K Env-specific CAR T cells similarly reduced"/>
  <result pre="melanoma patients [62]. HERV-K Env-specific CAR T cells similarly reduced" exact="tumor" post="burden and metastasis in mouse xenograft models [63]. Research"/>
  <result pre="HERV-K Env-specific CAR T cells similarly reduced tumor burden and" exact="metastasis" post="in mouse xenograft models [63]. Research in pancreatic cancer"/>
  <result pre="burden and metastasis in mouse xenograft models [63]. Research in" exact="pancreatic cancer" post="also demonstrated that HERV-K(HML2) Env regulates the Ras-ERK pathway,"/>
  <result pre="and metastasis in mouse xenograft models [63]. Research in pancreatic" exact="cancer" post="also demonstrated that HERV-K(HML2) Env regulates the Ras-ERK pathway,"/>
  <result pre="Env in vitro and in vivo reduced the growth of" exact="pancreatic cancer" post="and metastasis [64]. Finally, the env-encoded H17 protein of"/>
  <result pre="in vitro and in vivo reduced the growth of pancreatic" exact="cancer" post="and metastasis [64]. Finally, the env-encoded H17 protein of"/>
  <result pre="and in vivo reduced the growth of pancreatic cancer and" exact="metastasis" post="[64]. Finally, the env-encoded H17 protein of HERV-H was"/>
  <result pre="of HERV-H was found to induce epithelial-to-mesenchymal transition (EMT) in" exact="tumor" post="cells and recruit immunoregulatory suppressor cells, suggesting its contributory"/>
  <result pre="and recruit immunoregulatory suppressor cells, suggesting its contributory role in" exact="tumor" post="metastasis and immune escape [65]. These findings support the"/>
  <result pre="recruit immunoregulatory suppressor cells, suggesting its contributory role in tumor" exact="metastasis" post="and immune escape [65]. These findings support the role"/>
  <result pre="HML10 and HML6 groups [70,71]. 10. HERV-Induced Immune Responsesâ€&quot;Implication for" exact="Cancer" post="Management Since HERV elements are transcriptionally controlled in normal"/>
  <result pre="Management Since HERV elements are transcriptionally controlled in normal tissues," exact="cancer" post="environment can likely lead to their epigenetic dysregulation, possibly"/>
  <result pre="vitro, cytotoxic T cells that target HERV-K(HML6)-encoded epitope effectively lyse" exact="melanoma" post="cells [62]. Patients with a past history of seminomas"/>
  <result pre="cells [62]. Patients with a past history of seminomas and" exact="limited" post="healthy individuals also possessed defined HERV-K(HML2)-derived epitope recognized by"/>
  <result pre="defined HERV-K(HML2)-derived epitope recognized by CD8+ T cells [72]. In" exact="renal cell carcinoma" post="(RCC) patients who received hematopoietic stem-cell transplantation, CD8+ T"/>
  <result pre="epitope recognized by CD8+ T cells [72]. In renal cell" exact="carcinoma" post="(RCC) patients who received hematopoietic stem-cell transplantation, CD8+ T"/>
  <result pre="HERV-E antigen were produced after the transplantation and led to" exact="disease" post="regression [73]. On the contrary, humoral response against HERV"/>
  <result pre="[73]. On the contrary, humoral response against HERV usually reflects" exact="disease" post="severity of cancer. For instance, HERV-K(HML2)-reactive antibodies were found"/>
  <result pre="HERV-K(HML2)-reactive antibodies were found in the sera of germ cell" exact="tumor" post="patients and the decreased titer correlated with longer survival"/>
  <result pre="correlated with longer survival [74]. Similarly, HERV-K(HML2) antibody reactivity in" exact="melanoma" post="patients predicts poor prognosis [75]. Antibodies specific to cancer-associated"/>
  <result pre="to cancer-associated HERV could therefore serve as an indicator of" exact="disease" post="progression and treatment effectiveness. In conjunction with the above,"/>
  <result pre="are known to trigger innate immune responses due to their" exact="viral" post="features (viral mimicry effect). HERV antigens (including nucleic acids"/>
  <result pre="the induced expression of HERV molecules as a sign of" exact="infection" post="by an exogenous virus and mounts an antiviral innate"/>
  <result pre="TLR3 pathway to induce an antiviral innate immune state against" exact="infection" post="by other exogenous retroviruses [45]. Another example is the"/>
  <result pre="as IL-1Î², IL-6, and TNF-Î± [77]. Finally, with implication for" exact="cancer" post="treatment, it has been recently shown that radiation-induced ERV-associated"/>
  <result pre="been recently shown that radiation-induced ERV-associated dsRNA transcription in mouse" exact="melanoma" post="cells promotes the activation of the innate antiviral MDA5/MAVS/TBK1"/>
  <result pre="resulting in anti-tumor response [78]. The overall consequence of this" exact="viral" post="mimicry is thought to weaken the cancer cells and"/>
  <result pre="consequence of this viral mimicry is thought to weaken the" exact="cancer" post="cells and attract cytotoxic T cells to the previously"/>
  <result pre="cells and attract cytotoxic T cells to the previously â€œimmune-coldâ€�" exact="tumor" post="microenvironment, leading to tumor destruction. In summary, HERV-encoded antigens/proteins"/>
  <result pre="T cells to the previously â€œimmune-coldâ€� tumor microenvironment, leading to" exact="tumor" post="destruction. In summary, HERV-encoded antigens/proteins could act as potential"/>
  <result pre="targets to trigger immune-mediated cascades that could be beneficial for" exact="tumor" post="management. Provoking such mechanisms has promising significance in onco-immunotherapies."/>
  <result pre="promising significance in onco-immunotherapies. 11. Immunotherapeutic Strategies Targeting HERV for" exact="Cancer" post="Treatment Due to the potential contribution of HERV expression"/>
  <result pre="encoded by individual HERV members are found in the active" exact="multiple sclerosis" post="(MS) patients [79,80]. Temelimab, also known as GNbAC1, is"/>
  <result pre="elicit a desirable response against HERV-mediated pathophysiological mechanisms in MS" exact="disease" post="progression. This HERV-targeting approach could similarly be applied for"/>
  <result pre="disease progression. This HERV-targeting approach could similarly be applied for" exact="cancer" post="treatment, and the development of prophylactic vaccines against HERV-derived"/>
  <result pre="of HERV as the target for anti-cancer strategies is currently" exact="limited" post="by the still incomplete knowledge of their role in"/>
  <result pre="target for anti-cancer strategies is currently limited by the still" exact="incomplete" post="knowledge of their role in the development and progression"/>
  <result pre="immune recognition [82,83,84]. Kraus et al. [85] developed a recombinant" exact="vaccinia" post="virus that expressed HERV-K(HML2) Env protein (MVA-HKenv) and tested"/>
  <result pre="Env protein (MVA-HKenv) and tested it in a syngeneic mouse" exact="tumor" post="model where HERV-K Env was expressed in the murine"/>
  <result pre="tumor model where HERV-K Env was expressed in the murine" exact="renal cancer" post="cells (RLZ-HKenv cells). Intravenous injection of RLZ-HKenv cells in"/>
  <result pre="model where HERV-K Env was expressed in the murine renal" exact="cancer" post="cells (RLZ-HKenv cells). Intravenous injection of RLZ-HKenv cells in"/>
  <result pre="injection of RLZ-HKenv cells in the BALB/c mice led to" exact="metastatic" post="lung cancer. A single vaccination with MVA-HKenv drastically resolved"/>
  <result pre="of RLZ-HKenv cells in the BALB/c mice led to metastatic" exact="lung cancer." post="A single vaccination with MVA-HKenv drastically resolved the pulmonary"/>
  <result pre="lung cancer. A single vaccination with MVA-HKenv drastically resolved the" exact="pulmonary" post="tumor nodules, suggesting the efficacy of the vaccine. The"/>
  <result pre="cancer. A single vaccination with MVA-HKenv drastically resolved the pulmonary" exact="tumor" post="nodules, suggesting the efficacy of the vaccine. The vaccinated"/>
  <result pre="immunity against RLZ-HKenv cells, which can be explained by T-cell-mediated" exact="tumor" post="cell lysis induced by the vaccine [85]. This group"/>
  <result pre="promising target to elicit a long-lived T cell response against" exact="tumor" post="in the murine model [86]. A similar strategy has"/>
  <result pre="mice, which could stimulate T cell response to inhibit murine" exact="colorectal tumor" post="growth [87]. Likewise, another group investigated the extent of"/>
  <result pre="which could stimulate T cell response to inhibit murine colorectal" exact="tumor" post="growth [87]. Likewise, another group investigated the extent of"/>
  <result pre="is required to encourage further immunotherapeutic progression targeting HERV in" exact="cancer" post="therapy. 12. Inhibiting DNA Methylation to Induce Anti-Tumor Response"/>
  <result pre="to Induce Anti-Tumor Response through HERV Signature Upregulation as a" exact="Cancer" post="Treatment Strategy As mentioned earlier, HERVs are typically transcriptionally"/>
  <result pre="sequences through the inhibition of methyl transferases may contribute to" exact="viral" post="mimicry effect and/or enhanced expression of neoantigens that can"/>
  <result pre="anti-tumor effect [90]. A similar observation was also found in" exact="ovarian cancer" post="cells, in which a combination of the histone methyltransferase"/>
  <result pre="effect [90]. A similar observation was also found in ovarian" exact="cancer" post="cells, in which a combination of the histone methyltransferase"/>
  <result pre="produced a synergistic anti-tumor effect that was associated with enhanced" exact="viral" post="mimicry from the upregulated HERV expression [90]. Indeed, the"/>
  <result pre="and MAVS-associated dsRNA sensing pathways that accompanied ERV upregulation in" exact="ovarian cancer" post="cells, and this higher viral defense signature expression also"/>
  <result pre="MAVS-associated dsRNA sensing pathways that accompanied ERV upregulation in ovarian" exact="cancer" post="cells, and this higher viral defense signature expression also"/>
  <result pre="accompanied ERV upregulation in ovarian cancer cells, and this higher" exact="viral" post="defense signature expression also correlates with tumor sensitivity to"/>
  <result pre="and this higher viral defense signature expression also correlates with" exact="tumor" post="sensitivity to immune checkpoint therapy, particularly with the addition"/>
  <result pre="onco-immunotherapies. 13. Antiviral Targeting of HERV as a Strategy for" exact="Cancer" post="Treatment Due to their similarity with HIV, it is"/>
  <result pre="through ARVs as an approach to defer their impact on" exact="disease" post="progression. In the case of colorectal cancer, where HERV-H"/>
  <result pre="defer their impact on disease progression. In the case of" exact="colorectal cancer," post="where HERV-H were found in almost 50% of samples"/>
  <result pre="need to justify the clinical impact of HERV-H blockade in" exact="colorectal cancer" post="treatment. This points to potential usage of antiviral therapy"/>
  <result pre="to justify the clinical impact of HERV-H blockade in colorectal" exact="cancer" post="treatment. This points to potential usage of antiviral therapy"/>
  <result pre="to their close association with HIV. Although initially antivirals targeting" exact="viral" post="RT were explored, ARVs that can block all significant"/>
  <result pre="supported by the observation that HIV patients may have a" exact="lower" post="risk of developing MS than the others, possibly due"/>
  <result pre="on HML2 infectivity, the same group tested VSV-G pseudotyped HML2" exact="infection" post="in HeLa cells in the presence of RT inhibitors."/>
  <result pre="abacavir and zidovudine both exhibited an inhibitory effect on HML2" exact="infection" post="in a dose-dependent fashion [95]. Contribution of RT activity"/>
  <result pre="of RT activity in cellular transformation was also investigated in" exact="melanoma" post="and prostate cancer cell lines. RT activity was halted"/>
  <result pre="activity in cellular transformation was also investigated in melanoma and" exact="prostate cancer" post="cell lines. RT activity was halted by the use"/>
  <result pre="in cellular transformation was also investigated in melanoma and prostate" exact="cancer" post="cell lines. RT activity was halted by the use"/>
  <result pre="and RT-encoding LINE-1 elements were downregulated by RNA interference (RNAi)." exact="Reduced" post="RT activity resulted in downsized cell proliferation, enhanced morphological"/>
  <result pre="gene expression patterns in vitro. Moreover, the tumorigenic phenotype of" exact="prostate carcinoma" post="cells in the xenograft nude mice model was attenuated"/>
  <result pre="expression patterns in vitro. Moreover, the tumorigenic phenotype of prostate" exact="carcinoma" post="cells in the xenograft nude mice model was attenuated"/>
  <result pre="and differentiation and may serve as a novel target in" exact="cancer" post="therapy. Alongside, the inhibitory potential of HIV protease and"/>
  <result pre="reports, it appears possible that the HERVs expressed in varied" exact="cancer" post="types can be counter-attacked by employing ARVs used in"/>
  <result pre="specific physiological and pathological conditions. The exceptional depth at which" exact="cancer" post="genomes are examined indicates that HERVs may have completely"/>
  <result pre="time of novel integration. Nevertheless, HERVs do still contribute to" exact="cancer" post="pathology by distinct and often indirect mechanisms (Figure 1)."/>
  <result pre="selectively identified to possess tumor-associated properties that are significant in" exact="tumor" post="carcinogenesis [50]. However, whether HERV is a causative agent"/>
  <result pre="is a causative agent or merely a consequence of the" exact="disease" post="is still vague, since HERV activation or HERV-encoded protein"/>
  <result pre="vague, since HERV activation or HERV-encoded protein expression at the" exact="disease" post="microenvironment alone is insufficient to prove their pathogenic potency."/>
  <result pre="pathogenic potency. With a better understanding of the link between" exact="HIV infection" post="and HERVs, it is evident that HIV can alter"/>
  <result pre="potency. With a better understanding of the link between HIV" exact="infection" post="and HERVs, it is evident that HIV can alter"/>
  <result pre="the well-characterized increased risk for HIV-associated malignancies, HERV dysregulation by" exact="HIV infection" post="can further prompt such a vicious cycle, providing possible"/>
  <result pre="well-characterized increased risk for HIV-associated malignancies, HERV dysregulation by HIV" exact="infection" post="can further prompt such a vicious cycle, providing possible"/>
  <result pre="the need for the development of immunotherapy for rapidly evolving" exact="cancer" post="types. Due to HERVsâ€™ background of retroviral origin and"/>
  <result pre="cancer types. Due to HERVsâ€™ background of retroviral origin and" exact="partial" post="immune tolerance, these aliens inside us have become a"/>
  <result pre="target for future onco-immunotherapy. Understanding the role of HERV in" exact="cancer" post="progression is analogously essential to building a steady approach"/>
  <result pre="progression is analogously essential to building a steady approach to" exact="cancer" post="management. Funding C.-H.L. has received PhD fellowship from the"/>
  <result pre="C.-H.L. has received PhD fellowship from the Canadian Network on" exact="Hepatitis" post="C (CanHepC). CanHepC is funded by a joint initiative"/>
  <result pre="to L.-T.L.) and the MOST-CNR (National Research Council of Italy)" exact="Joint" post="Research Project (MOST107-2911-I-038-501 and MOST108-2911-I-038-501 to L.-T.L. and E.T.)."/>
  <result pre="retroviruses; mosaic forms are commonRetrovirology201613710.1186/s12977-015-0232-y26800882 4.GrandiN.TramontanoE.Human Endogenous Retroviruses Are Ancient" exact="Acquired" post="Elements Still Shaping Innate Immune ResponsesFront. Immunol.20189203910.3389/fimmu.2018.0203930250470 5.GrandiN.TramontanoE.HERV Envelope"/>
  <result pre="Immunol.20189203910.3389/fimmu.2018.0203930250470 5.GrandiN.TramontanoE.HERV Envelope Proteins: Physiological Role and Pathogenic Potential in" exact="Cancer" post="and AutoimmunityFront. Microbiol.2018946210.3389/fmicb.2018.0046229593697 6.VottelerJ.SchubertU.Human Immunodeficiency Viruses: Molecular BiologyEncyclopedia of"/>
  <result pre="Role and Pathogenic Potential in Cancer and AutoimmunityFront. Microbiol.2018946210.3389/fmicb.2018.0046229593697 6.VottelerJ.SchubertU.Human" exact="Immunodeficiency" post="Viruses: Molecular BiologyEncyclopedia of Virology3rd ed.MahyB.W.J.van RegenmortelM.H.V.Elsevier Ltd.Amsterdam, The"/>
  <result pre="consequences of ancient endogenous retrovirusesNat. Rev. Microbiol.20191735537010.1038/s41579-019-0189-230962577 9.Marino-MerloF.BalestrieriE.MatteucciC.MastinoA.GrelliS.MacchiB.Antiretroviral Therapy in" exact="HTLV-1" post="Infection: An Updated OverviewPathogens2020934210.3390/pathogens9050342 10.FutschN.MahieuxR.DutartreH.HTLV-1, the Other Pathogenic yet"/>
  <result pre="Retrovirus: From Transmission to Therapeutic TreatmentViruses201810110.3390/v10010001 11.collab: National Center for" exact="Infectious" post="Diseases Division of HIV/AIDSCastroK.G.WardJ.W.SlutskerL.BuehlerJ.W.JaffeH.W.BerkelmanR.L.1993 revised classification system for HIV"/>
  <result pre="From Transmission to Therapeutic TreatmentViruses201810110.3390/v10010001 11.collab: National Center for Infectious" exact="Diseases" post="Division of HIV/AIDSCastroK.G.WardJ.W.SlutskerL.BuehlerJ.W.JaffeH.W.BerkelmanR.L.1993 revised classification system for HIV infection"/>
  <result pre="for Infectious Diseases Division of HIV/AIDSCastroK.G.WardJ.W.SlutskerL.BuehlerJ.W.JaffeH.W.BerkelmanR.L.1993 revised classification system for" exact="HIV infection" post="and expanded surveillance case definition for AIDS among adolescents"/>
  <result pre="Infectious Diseases Division of HIV/AIDSCastroK.G.WardJ.W.SlutskerL.BuehlerJ.W.JaffeH.W.BerkelmanR.L.1993 revised classification system for HIV" exact="infection" post="and expanded surveillance case definition for AIDS among adolescents"/>
  <result pre="AIDS among adolescents and adultsMMWR Recomm. Rep.19924111910.1093/clinids/17.4.802 12.Martinez-MazaO.BreenE.C.B-cell activation and" exact="lymphoma" post="in patients with HIVCurr. Opin. Oncol.20021452853210.1097/00001622-200209000-0000912192272 13.CasperC.CraneH.MenonM.MoneyD.HIV/AIDS Comorbidities: Impact"/>
  <result pre="13.CasperC.CraneH.MenonM.MoneyD.HIV/AIDS Comorbidities: Impact on Cancer, Noncommunicable Diseases, and Reproductive HealthMajor" exact="Infectious" post="Diseases3rd ed.HolmesK.K.BertozziS.BloomB.R.JhaP.The International Bank for Reconstruction and Development/The World"/>
  <result pre="and Development/The World BankWashington, DC, USA201710.1596/978-1-4648-0524-0_ch3 14.De MartelC.ShielsM.S.FranceschiS.SimardE.P.VignatJ.HallH.I.EngelsE.A.PlummerM.Cancers attributable to" exact="infections" post="among adults with HIV in the United StatesAIDS2015292173218110.1097/QAD.000000000000080826182198 15.DubrowR.SilverbergM.J.ParkL.S.CrothersK.JusticeA.C.HIV"/>
  <result pre="United StatesAIDS2015292173218110.1097/QAD.000000000000080826182198 15.DubrowR.SilverbergM.J.ParkL.S.CrothersK.JusticeA.C.HIV infection, aging, and immune function: Implications for" exact="cancer" post="risk and preventionCurr. Opin. Oncol.20122450651610.1097/CCO.0b013e328355e13122759737 16.BohliusJ.FosterC.NaiduG.SengayiM.TurkovaA.Cancer in adolescents and"/>
  <result pre="young adults living with HIVCurr. Opin. HIV AIDS20181319620310.1097/COH.000000000000046029461329 17.MaurerT.PonteM.LeslieK.HIV-associated Kaposiâ€™s" exact="sarcoma" post="with a high CD4 count and a low viral"/>
  <result pre="Kaposiâ€™s sarcoma with a high CD4 count and a low" exact="viral" post="loadN. Engl. J. Med.20073571352135310.1056/NEJMc07050817898112 18.RobbinsH.A.ShielsM.S.PfeifferR.M.EngelsE.A.Epidemiologic contributions to recent cancer"/>
  <result pre="low viral loadN. Engl. J. Med.20073571352135310.1056/NEJMc07050817898112 18.RobbinsH.A.ShielsM.S.PfeifferR.M.EngelsE.A.Epidemiologic contributions to recent" exact="cancer" post="trends among HIV-infected people in the United StatesAIDS20142888189010.1097/QAD.000000000000016324300545 19.Van"/>
  <result pre="widespread use of antiretroviral therapyAIDS2009232183219010.1097/QAD.0b013e328331d38419734774 20.YanikE.L.NapravnikS.ColeS.R.AchenbachC.J.GopalS.OlshanA.DittmerD.P.KitahataM.M.MugaveroM.J.SaagM.et al.Incidence and timing of" exact="cancer" post="in HIV-infected individuals following initiation of combination antiretroviral therapyClin."/>
  <result pre="individuals following initiation of combination antiretroviral therapyClin. Infect. Dis.20135775676410.1093/cid/cit36923735330 21.PicardA.BadoualC.HourseauM.HalimiC.PereH.DibF.BarryB.AlbertS.Human" exact="papilloma" post="virus prevalence in HIV patients with head and neck"/>
  <result pre="Dis.20135775676410.1093/cid/cit36923735330 21.PicardA.BadoualC.HourseauM.HalimiC.PereH.DibF.BarryB.AlbertS.Human papilloma virus prevalence in HIV patients with head" exact="and neck" post="squamous cell carcinomaAIDS2016301257126610.1097/QAD.000000000000103026807970 22.WilliamsA.B.DarraghT.M.VranizanK.OchiaC.MossA.R.PalefskyJ.M.Anal and cervical human papillomavirus infection"/>
  <result pre="papilloma virus prevalence in HIV patients with head and neck" exact="squamous cell" post="carcinomaAIDS2016301257126610.1097/QAD.000000000000103026807970 22.WilliamsA.B.DarraghT.M.VranizanK.OchiaC.MossA.R.PalefskyJ.M.Anal and cervical human papillomavirus infection and risk"/>
  <result pre="and neck squamous cell carcinomaAIDS2016301257126610.1097/QAD.000000000000103026807970 22.WilliamsA.B.DarraghT.M.VranizanK.OchiaC.MossA.R.PalefskyJ.M.Anal and cervical human papillomavirus" exact="infection" post="and risk of anal and cervical epithelial abnormalities in"/>
  <result pre="cervical human papillomavirus infection and risk of anal and cervical" exact="epithelial" post="abnormalities in human immunodeficiency virus-infected womenObstet. Gynecol.19948320521110.1016/0020-7292(94)90475-88290181 23.KowalkowskiM.A.MimsM.A.DayR.S.DuX.L.ChanW.ChiaoE.Y.Longer duration"/>
  <result pre="and risk of anal and cervical epithelial abnormalities in human" exact="immunodeficiency" post="virus-infected womenObstet. Gynecol.19948320521110.1016/0020-7292(94)90475-88290181 23.KowalkowskiM.A.MimsM.A.DayR.S.DuX.L.ChanW.ChiaoE.Y.Longer duration of combination antiretroviral therapy"/>
  <result pre="Among HIV-Infected Patients in the United StatesJ. Clin. Oncol.2015332376238310.1200/JCO.2014.59.596726077242 26.SigelK.MakinsonA.ThalerJ.Lung" exact="cancer" post="in persons with HIVCurr. Opin. HIV AIDS201712313810.1097/COH.000000000000032627607596 27.MdodoR.FrazierE.L.DubeS.R.MattsonC.L.SuttonM.Y.BrooksJ.T.SkarbinskiJ.Cigarette smoking"/>
  <result pre="smoking prevalence among adults with HIV compared with the general" exact="adult" post="population in the United States: Cross-sectional surveysAnn. Intern. Med.201516233534410.7326/M14-095425732274"/>
  <result pre="population in the United States: Cross-sectional surveysAnn. Intern. Med.201516233534410.7326/M14-095425732274 28.SheblF.M.EngelsE.A.GoedertJ.J.ChaturvediA.K.Pulmonary" exact="infections" post="and risk of lung cancer among persons with AIDSJ."/>
  <result pre="States: Cross-sectional surveysAnn. Intern. Med.201516233534410.7326/M14-095425732274 28.SheblF.M.EngelsE.A.GoedertJ.J.ChaturvediA.K.Pulmonary infections and risk of" exact="lung cancer" post="among persons with AIDSJ. Acquir. Immune Defic. Syndr.20105537537910.1097/QAI.0b013e3181eef4f720736841 29.CliffordG.M.LiseM.FranceschiS.EggerM.BouchardyC.KorolD.LeviF.EssS.JundtG.WandelerG.et"/>
  <result pre="Cross-sectional surveysAnn. Intern. Med.201516233534410.7326/M14-095425732274 28.SheblF.M.EngelsE.A.GoedertJ.J.ChaturvediA.K.Pulmonary infections and risk of lung" exact="cancer" post="among persons with AIDSJ. Acquir. Immune Defic. Syndr.20105537537910.1097/QAI.0b013e3181eef4f720736841 29.CliffordG.M.LiseM.FranceschiS.EggerM.BouchardyC.KorolD.LeviF.EssS.JundtG.WandelerG.et"/>
  <result pre="among persons with AIDSJ. Acquir. Immune Defic. Syndr.20105537537910.1097/QAI.0b013e3181eef4f720736841 29.CliffordG.M.LiseM.FranceschiS.EggerM.BouchardyC.KorolD.LeviF.EssS.JundtG.WandelerG.et al.Lung" exact="cancer" post="in the Swiss HIV Cohort Study: Role of smoking,"/>
  <result pre="cancer in the Swiss HIV Cohort Study: Role of smoking," exact="immunodeficiency" post="and pulmonary infectionBr. J. Cancer201210644745210.1038/bjc.2011.55822240797 30.PuronenC.E.FordE.S.UldrickT.S.Immunotherapy in People with"/>
  <result pre="the Swiss HIV Cohort Study: Role of smoking, immunodeficiency and" exact="pulmonary" post="infectionBr. J. Cancer201210644745210.1038/bjc.2011.55822240797 30.PuronenC.E.FordE.S.UldrickT.S.Immunotherapy in People with HIV and"/>
  <result pre="in Neurological DiseasesTrends Mol. Med.20182437939410.1016/j.molmed.2018.02.00729551251 44.MatteucciC.BalestrieriE.Argaw-DenbobaA.Sinibaldi-VallebonaP.Human endogenous retroviruses role in" exact="cancer" post="cell stemnessSemin. Cancer Biol.201853173010.1016/j.semcancer.2018.10.00130317035 45.ChenJ.ForoozeshM.QinZ.Transactivation of human endogenous retroviruses"/>
  <result pre="Mol. Med.20182437939410.1016/j.molmed.2018.02.00729551251 44.MatteucciC.BalestrieriE.Argaw-DenbobaA.Sinibaldi-VallebonaP.Human endogenous retroviruses role in cancer cell stemnessSemin." exact="Cancer" post="Biol.201853173010.1016/j.semcancer.2018.10.00130317035 45.ChenJ.ForoozeshM.QinZ.Transactivation of human endogenous retroviruses by tumor viruses"/>
  <result pre="cell stemnessSemin. Cancer Biol.201853173010.1016/j.semcancer.2018.10.00130317035 45.ChenJ.ForoozeshM.QinZ.Transactivation of human endogenous retroviruses by" exact="tumor" post="viruses and their functions in virus-associated malignanciesOncogenesis20198610.1038/s41389-018-0114-y30643113 46.ZhangM.LiangJ.Q.ZhengS.Expressional activation"/>
  <result pre="CubasA.A.BixbyL.M.LeeS.J.PandaA.GanesanS.BhanotG.WallenE.M.et al.Endogenous retroviral signatures predict immunotherapy response in clear cell" exact="renal cell" post="carcinomaJ. Clin. Investig.20181284804482010.1172/JCI12147630137025 50.RooneyM.S.ShuklaS.A.WuC.J.GetzG.HacohenN.Molecular and genetic properties of tumors"/>
  <result pre="pol gene of human endogenous retroviruses HERV-K and -W in" exact="leukemia" post="patientsArch. Virol.20171623639364410.1007/s00705-017-3526-728821995 52.Januszkiewicz-LewandowskaD.NowickaK.RembowskaJ.FichnaM.ZurawekM.DerwichK.NowakJ.Env gene expression of human endogenous retrovirus-k"/>
  <result pre="expression of human endogenous retrovirus-k and human endogenous retrovirus-w in" exact="childhood" post="acute leukemia cellsActa Haematol.201312923223710.1159/00034540723328642 53.KassiotisG.StoyeJ.P.Making a virtue of necessity:"/>
  <result pre="of human endogenous retrovirus-k and human endogenous retrovirus-w in childhood" exact="acute" post="leukemia cellsActa Haematol.201312923223710.1159/00034540723328642 53.KassiotisG.StoyeJ.P.Making a virtue of necessity: The"/>
  <result pre="human endogenous retrovirus-k and human endogenous retrovirus-w in childhood acute" exact="leukemia" post="cellsActa Haematol.201312923223710.1159/00034540723328642 53.KassiotisG.StoyeJ.P.Making a virtue of necessity: The pleiotropic"/>
  <result pre="prostate cancerNature200744859559910.1038/nature0602417671502 56.MareschiK.MontanariP.RassuM.GallianoI.DapraV.AdaminiA.CastigliaS.FagioliF.BergalloM.Human Endogenous Retrovirus-H and K Expression in Human" exact="Mesenchymal" post="Stem Cells as Potential Markers of StemnessIntervirology20196291410.1159/00049918531104062 57.Diaz-CarballoD.AcikelliA.H.KleinJ.JastrowH.DammannP.WyganowskiT.GuemuesC.GustmannS.BardenheuerW.MalakS.et al.Therapeutic"/>
  <result pre="of StemnessIntervirology20196291410.1159/00049918531104062 57.Diaz-CarballoD.AcikelliA.H.KleinJ.JastrowH.DammannP.WyganowskiT.GuemuesC.GustmannS.BardenheuerW.MalakS.et al.Therapeutic potential of antiviral drugs targeting chemorefractory" exact="colorectal adenocarcinoma" post="cells overexpressing endogenous retroviral elementsJ. Exp. Clin. Cancer Res.2015348110.1186/s13046-015-0199-526260344"/>
  <result pre="StemnessIntervirology20196291410.1159/00049918531104062 57.Diaz-CarballoD.AcikelliA.H.KleinJ.JastrowH.DammannP.WyganowskiT.GuemuesC.GustmannS.BardenheuerW.MalakS.et al.Therapeutic potential of antiviral drugs targeting chemorefractory colorectal" exact="adenocarcinoma" post="cells overexpressing endogenous retroviral elementsJ. Exp. Clin. Cancer Res.2015348110.1186/s13046-015-0199-526260344"/>
  <result pre="chemorefractory colorectal adenocarcinoma cells overexpressing endogenous retroviral elementsJ. Exp. Clin." exact="Cancer" post="Res.2015348110.1186/s13046-015-0199-526260344 58.Argaw-DenbobaA.BalestrieriE.SerafinoA.CiprianiC.BucciI.SorrentinoR.SciamannaI.GambacurtaA.Sinibaldi-VallebonaP.MatteucciC.HERV-K activation is strictly required to sustain CD133+"/>
  <result pre="Cancer Res.2015348110.1186/s13046-015-0199-526260344 58.Argaw-DenbobaA.BalestrieriE.SerafinoA.CiprianiC.BucciI.SorrentinoR.SciamannaI.GambacurtaA.Sinibaldi-VallebonaP.MatteucciC.HERV-K activation is strictly required to sustain CD133+" exact="melanoma" post="cells with stemness featuresJ. Exp. Clin. Cancer Res.2017362010.1186/s13046-016-0485-x28125999 59.ZhouF.LiM.WeiY.LinK.LuY.ShenJ.JohanningG.L.Wang-JohanningF.Activation"/>
  <result pre="to sustain CD133+ melanoma cells with stemness featuresJ. Exp. Clin." exact="Cancer" post="Res.2017362010.1186/s13046-016-0485-x28125999 59.ZhouF.LiM.WeiY.LinK.LuY.ShenJ.JohanningG.L.Wang-JohanningF.Activation of HERV-K Env protein is essential for"/>
  <result pre="59.ZhouF.LiM.WeiY.LinK.LuY.ShenJ.JohanningG.L.Wang-JohanningF.Activation of HERV-K Env protein is essential for tumorigenesis and" exact="metastasis" post="of breast cancer cellsOncotarget20167840938411710.18632/oncotarget.1145527557521 60.Wang-JohanningF.RycajK.PlummerJ.B.LiM.YinB.FrerichK.GarzaJ.G.ShenJ.LinK.YanP.et al.Immunotherapeutic potential of anti-human"/>
  <result pre="HERV-K Env protein is essential for tumorigenesis and metastasis of" exact="breast cancer" post="cellsOncotarget20167840938411710.18632/oncotarget.1145527557521 60.Wang-JohanningF.RycajK.PlummerJ.B.LiM.YinB.FrerichK.GarzaJ.G.ShenJ.LinK.YanP.et al.Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope"/>
  <result pre="Env protein is essential for tumorigenesis and metastasis of breast" exact="cancer" post="cellsOncotarget20167840938411710.18632/oncotarget.1145527557521 60.Wang-JohanningF.RycajK.PlummerJ.B.LiM.YinB.FrerichK.GarzaJ.G.ShenJ.LinK.YanP.et al.Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope"/>
  <result pre="potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting" exact="breast" post="tumorsJ. Natl. Cancer Inst.201210418921010.1093/jnci/djr54022247020 61.ZhouF.KrishnamurthyJ.WeiY.LiM.HuntK.JohanningG.L.CooperL.J.Wang-JohanningF.Chimeric antigen receptor T cells"/>
  <result pre="endogenous retrovirus-K envelope protein antibodies in targeting breast tumorsJ. Natl." exact="Cancer" post="Inst.201210418921010.1093/jnci/djr54022247020 61.ZhouF.KrishnamurthyJ.WeiY.LiM.HuntK.JohanningG.L.CooperL.J.Wang-JohanningF.Chimeric antigen receptor T cells targeting HERV-K inhibit"/>
  <result pre="Cancer Inst.201210418921010.1093/jnci/djr54022247020 61.ZhouF.KrishnamurthyJ.WeiY.LiM.HuntK.JohanningG.L.CooperL.J.Wang-JohanningF.Chimeric antigen receptor T cells targeting HERV-K inhibit" exact="breast cancer" post="and its metastasis through downregulation of RasOncoimmunology20154e104758210.1080/2162402X.2015.104758226451325 62.SchiavettiF.ThonnardJ.ColauD.BoonT.CoulieP.G.A human"/>
  <result pre="Inst.201210418921010.1093/jnci/djr54022247020 61.ZhouF.KrishnamurthyJ.WeiY.LiM.HuntK.JohanningG.L.CooperL.J.Wang-JohanningF.Chimeric antigen receptor T cells targeting HERV-K inhibit breast" exact="cancer" post="and its metastasis through downregulation of RasOncoimmunology20154e104758210.1080/2162402X.2015.104758226451325 62.SchiavettiF.ThonnardJ.ColauD.BoonT.CoulieP.G.A human"/>
  <result pre="receptor T cells targeting HERV-K inhibit breast cancer and its" exact="metastasis" post="through downregulation of RasOncoimmunology20154e104758210.1080/2162402X.2015.104758226451325 62.SchiavettiF.ThonnardJ.ColauD.BoonT.CoulieP.G.A human endogenous retroviral sequence"/>
  <result pre="62.SchiavettiF.ThonnardJ.ColauD.BoonT.CoulieP.G.A human endogenous retroviral sequence encoding an antigen recognized on" exact="melanoma" post="by cytolytic T lymphocytesCancer Res.2002625510551612359761 63.KrishnamurthyJ.RabinovichB.A.MiT.SwitzerK.C.OlivaresS.MaitiS.N.PlummerJ.B.SinghH.KumaresanP.R.HulsH.M.et al.Genetic Engineering of"/>
  <result pre="T Cells to Target HERV-K, an Ancient Retrovirus on MelanomaClin." exact="Cancer" post="Res.2015213241325110.1158/1078-0432.CCR-14-319725829402 64.LiM.RadvanyiL.YinB.RycajK.LiJ.ChivukulaR.LinK.LuY.ShenJ.ChangD.Z.et al.Downregulation of Human Endogenous Retrovirus Type K"/>
  <result pre="Res.2015213241325110.1158/1078-0432.CCR-14-319725829402 64.LiM.RadvanyiL.YinB.RycajK.LiJ.ChivukulaR.LinK.LuY.ShenJ.ChangD.Z.et al.Downregulation of Human Endogenous Retrovirus Type K (HERV-K)" exact="Viral" post="env RNA in Pancreatic Cancer Cells Decreases Cell Proliferation"/>
  <result pre="Human Endogenous Retrovirus Type K (HERV-K) Viral env RNA in" exact="Pancreatic Cancer" post="Cells Decreases Cell Proliferation and Tumor GrowthClin. Cancer Res.2017235892591110.1158/1078-0432.CCR-17-000128679769"/>
  <result pre="Endogenous Retrovirus Type K (HERV-K) Viral env RNA in Pancreatic" exact="Cancer" post="Cells Decreases Cell Proliferation and Tumor GrowthClin. Cancer Res.2017235892591110.1158/1078-0432.CCR-17-000128679769"/>
  <result pre="env RNA in Pancreatic Cancer Cells Decreases Cell Proliferation and" exact="Tumor" post="GrowthClin. Cancer Res.2017235892591110.1158/1078-0432.CCR-17-000128679769 65.Kudo-SaitoC.YuraM.YamamotoR.KawakamiY.Induction of immunoregulatory CD271+ cells by"/>
  <result pre="in Pancreatic Cancer Cells Decreases Cell Proliferation and Tumor GrowthClin." exact="Cancer" post="Res.2017235892591110.1158/1078-0432.CCR-17-000128679769 65.Kudo-SaitoC.YuraM.YamamotoR.KawakamiY.Induction of immunoregulatory CD271+ cells by metastatic tumor"/>
  <result pre="Tumor GrowthClin. Cancer Res.2017235892591110.1158/1078-0432.CCR-17-000128679769 65.Kudo-SaitoC.YuraM.YamamotoR.KawakamiY.Induction of immunoregulatory CD271+ cells by" exact="metastatic" post="tumor cells that express human endogenous retrovirus HCancer Res.2014741361137010.1158/0008-5472.CAN-13-134924590808"/>
  <result pre="GrowthClin. Cancer Res.2017235892591110.1158/1078-0432.CCR-17-000128679769 65.Kudo-SaitoC.YuraM.YamamotoR.KawakamiY.Induction of immunoregulatory CD271+ cells by metastatic" exact="tumor" post="cells that express human endogenous retrovirus HCancer Res.2014741361137010.1158/0008-5472.CAN-13-134924590808 66.DenneM.SauterM.ArmbruesterV.LichtJ.D.RoemerK.Mueller-LantzschN.Physical"/>
  <result pre="human endogenous retrovirus proteins Np9 and rec with the promyelocytic" exact="leukemia" post="zinc finger proteinJ. Virol.2007815607561610.1128/JVI.02771-0617360752 67.KaufmannS.SauterM.SchmittM.BaumertB.BestB.BoeseA.RoemerK.Mueller-LantzschN.Human endogenous retrovirus protein Rec"/>
  <result pre="patients with seminomaAIDS Res. Hum. Retrovir.200622525610.1089/aid.2006.22.5216438646 73.TakahashiY.HarashimaN.KajigayaS.YokoyamaH.CherkasovaE.McCoyJ.P.HanadaK.MenaO.KurlanderR.TawabA.et al.Regression of human" exact="kidney cancer" post="following allogeneic stem cell transplantation is associated with recognition"/>
  <result pre="with seminomaAIDS Res. Hum. Retrovir.200622525610.1089/aid.2006.22.5216438646 73.TakahashiY.HarashimaN.KajigayaS.YokoyamaH.CherkasovaE.McCoyJ.P.HanadaK.MenaO.KurlanderR.TawabA.et al.Regression of human kidney" exact="cancer" post="following allogeneic stem cell transplantation is associated with recognition"/>
  <result pre="J. Cancer200411045946110.1002/ijc.1164915095315 75.HahnS.UgurelS.HanschmannK.M.StrobelH.TonderaC.SchadendorfD.LowerJ.LowerR.Serological response to human endogenous retrovirus K in" exact="melanoma" post="patients correlates with survival probabilityAIDS Res. Hum. Retrovir.20082471772310.1089/aid.2007.028618462078 76.HurstT.P.MagiorkinisG.Activation"/>
  <result pre="al.Human endogenous retrovirus type W envelope expression in blood and" exact="brain" post="cells provides new insights into multiple sclerosis diseaseMult. Scler."/>
  <result pre="expression in blood and brain cells provides new insights into" exact="multiple sclerosis" post="diseaseMult. Scler. J.2012181721173610.1177/1352458512441381 80.LaskaM.J.BrudekT.NissenK.K.ChristensenT.Moller-LarsenA.PetersenT.NexoB.A.Expression of HERV-Fc1, a human endogenous"/>
  <result pre="82.Wang-JohanningF.RadvanyiL.RycajK.PlummerJ.B.YanP.SastryK.J.PiyathilakeC.J.HuntK.K.JohanningG.L.Human endogenous retrovirus K triggers an antigen-specific immune response in" exact="breast cancer" post="patientsCancer Res.2008685869587710.1158/0008-5472.CAN-07-683818632641 83.RycajK.PlummerJ.B.YinB.LiM.GarzaJ.RadvanyiL.RamondettaL.M.LinK.JohanningG.L.TangD.G.et al.Cytotoxicity of human endogenous retrovirus K-specific"/>
  <result pre="endogenous retrovirus K triggers an antigen-specific immune response in breast" exact="cancer" post="patientsCancer Res.2008685869587710.1158/0008-5472.CAN-07-683818632641 83.RycajK.PlummerJ.B.YinB.LiM.GarzaJ.RadvanyiL.RamondettaL.M.LinK.JohanningG.L.TangD.G.et al.Cytotoxicity of human endogenous retrovirus K-specific"/>
  <result pre="al.Cytotoxicity of human endogenous retrovirus K-specific T cells toward autologous" exact="ovarian cancer" post="cellsClin. Cancer Res.20152147148310.1158/1078-0432.CCR-14-038825370465 84.CherkasovaE.ScrivaniC.DohS.WeismanQ.TakahashiY.HarashimaN.YokoyamaH.SrinivasanR.LinehanW.M.LermanM.I.et al.Detection of an Immunogenic HERV-E"/>
  <result pre="of human endogenous retrovirus K-specific T cells toward autologous ovarian" exact="cancer" post="cellsClin. Cancer Res.20152147148310.1158/1078-0432.CCR-14-038825370465 84.CherkasovaE.ScrivaniC.DohS.WeismanQ.TakahashiY.HarashimaN.YokoyamaH.SrinivasanR.LinehanW.M.LermanM.I.et al.Detection of an Immunogenic HERV-E"/>
  <result pre="endogenous retrovirus K-specific T cells toward autologous ovarian cancer cellsClin." exact="Cancer" post="Res.20152147148310.1158/1078-0432.CCR-14-038825370465 84.CherkasovaE.ScrivaniC.DohS.WeismanQ.TakahashiY.HarashimaN.YokoyamaH.SrinivasanR.LinehanW.M.LermanM.I.et al.Detection of an Immunogenic HERV-E Envelope with"/>
  <result pre="Cancer Res.20152147148310.1158/1078-0432.CCR-14-038825370465 84.CherkasovaE.ScrivaniC.DohS.WeismanQ.TakahashiY.HarashimaN.YokoyamaH.SrinivasanR.LinehanW.M.LermanM.I.et al.Detection of an Immunogenic HERV-E Envelope with" exact="Selective" post="Expression in Clear Cell Kidney CancerCancer Res.2016762177218510.1158/0008-5472.CAN-15-313926862115 85.KrausB.FischerK.BuchnerS.M.WelsW.S.LowerR.SlivaK.SchnierleB.S.Vaccination directed"/>
  <result pre="an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell" exact="Kidney" post="CancerCancer Res.2016762177218510.1158/0008-5472.CAN-15-313926862115 85.KrausB.FischerK.BuchnerS.M.WelsW.S.LowerR.SlivaK.SchnierleB.S.Vaccination directed against the human endogenous retrovirus-K"/>
  <result pre="85.KrausB.FischerK.BuchnerS.M.WelsW.S.LowerR.SlivaK.SchnierleB.S.Vaccination directed against the human endogenous retrovirus-K envelope protein inhibits" exact="tumor" post="growth in a murine model systemPLoS ONE20138e7275610.1371/journal.pone.007275624023643 86.KrausB.FischerK.SlivaK.SchnierleB.S.Vaccination directed"/>
  <result pre="Rev. Cancer20191915116110.1038/s41568-019-0109-930723290 90.LiuM.ThomasS.L.DeWittA.K.ZhouW.MadajZ.B.OhtaniH.BaylinS.B.LiangG.JonesP.A.Dual Inhibition of DNA and Histone Methyltransferases Increases" exact="Viral" post="Mimicry in Ovarian Cancer CellsCancer Res.2018785754576610.1158/0008-5472.CAN-17-395330185548 91.ChiappinelliK.B.StrisselP.L.DesrichardA.LiH.HenkeC.AkmanB.HeinA.RoteN.S.CopeL.M.SnyderA.et al.Inhibiting DNA"/>
  <result pre="of DNA and Histone Methyltransferases Increases Viral Mimicry in Ovarian" exact="Cancer" post="CellsCancer Res.2018785754576610.1158/0008-5472.CAN-17-395330185548 91.ChiappinelliK.B.StrisselP.L.DesrichardA.LiH.HenkeC.AkmanB.HeinA.RoteN.S.CopeL.M.SnyderA.et al.Inhibiting DNA Methylation Causes an Interferon"/>
  <result pre="Res.2018785754576610.1158/0008-5472.CAN-17-395330185548 91.ChiappinelliK.B.StrisselP.L.DesrichardA.LiH.HenkeC.AkmanB.HeinA.RoteN.S.CopeL.M.SnyderA.et al.Inhibiting DNA Methylation Causes an Interferon Response in" exact="Cancer" post="via dsRNA Including Endogenous RetrovirusesCell201516297498610.1016/j.cell.2015.07.01126317466 92.WentzensenN.CoyJ.F.KnaebelH.P.LinnebacherM.WilzB.GebertJ.von Knebel DoeberitzM.Expression of"/>
  <result pre="93.PerotP.MullinsC.S.NavilleM.BressanC.HuhnsM.GockM.KuhnF.VolffJ.N.Trillet-LenoirV.LinnebacherM.et al.Expression of young HERV-H loci in the course of" exact="colorectal carcinoma" post="and correlation with molecular subtypesOncotarget20156400954011110.18632/oncotarget.553926517682 94.MorandiE.TanasescuR.TarlintonR.E.Constantin-TeodosiuD.GranB.Do Antiretroviral Drugs Protect"/>
  <result pre="al.Expression of young HERV-H loci in the course of colorectal" exact="carcinoma" post="and correlation with molecular subtypesOncotarget20156400954011110.18632/oncotarget.553926517682 94.MorandiE.TanasescuR.TarlintonR.E.Constantin-TeodosiuD.GranB.Do Antiretroviral Drugs Protect"/>
  <result pre="and correlation with molecular subtypesOncotarget20156400954011110.18632/oncotarget.553926517682 94.MorandiE.TanasescuR.TarlintonR.E.Constantin-TeodosiuD.GranB.Do Antiretroviral Drugs Protect from" exact="Multiple" post="Sclerosis by Inhibiting Expression of MS-Associated Retrovirus?Front. Immunol.20189309210.3389/fimmu.2018.0309230740110 95.TyagiR.LiW.ParadesD.BianchetM.A.NathA.Inhibition"/>
  <result pre="antiretroviral drugsRetrovirology2017142110.1186/s12977-017-0347-428330477 96.SciamannaI.LandriscinaM.PittoggiC.QuirinoM.MearelliC.BeraldiR.MatteiE.SerafinoA.CassanoA.Sinibaldi-VallebonaP.et al.Inhibition of endogenous reverse transcriptase antagonizes human" exact="tumor" post="growthOncogene2005243923393110.1038/sj.onc.120856215806170 97.SubramanianR.P.WildschutteJ.H.RussoC.CoffinJ.M.Identification, characterization, and comparative genomic distribution of the"/>
  <result pre="of the HIVâ€&quot; and HERVâ€&quot;cancer relationships and potential treatment strategies." exact="HIV infection" post="creates a dysregulated environment with chronic inflammation and immunosuppression"/>
  <result pre="the HIVâ€&quot; and HERVâ€&quot;cancer relationships and potential treatment strategies. HIV" exact="infection" post="creates a dysregulated environment with chronic inflammation and immunosuppression"/>
  <result pre="potential treatment strategies. HIV infection creates a dysregulated environment with" exact="chronic" post="inflammation and immunosuppression that aid oncovirus transformation and cancer"/>
  <result pre="with chronic inflammation and immunosuppression that aid oncovirus transformation and" exact="cancer" post="development (solid red arrows). Strategies to preclude HIV-related cancers"/>
  <result pre="elements have been found in various cancers, potentially contributing to" exact="cancer" post="development (solid blue arrows). The aberrant expression of HERV"/>
  <result pre="blue arrows). The aberrant expression of HERV elements has a" exact="viral" post="mimicry effect that triggers innate and adaptive immune responses"/>
 </snippets>
</snippetsTree>
